Literature DB >> 27586204

In-depth mutational analyses of colorectal neuroendocrine carcinomas with adenoma or adenocarcinoma components.

Christine Woischke1, Christian W Schaaf1, Hui-Min Yang2,3, Michael Vieth4, Lothar Veits4, Helene Geddert5, Bruno Märkl6, Peter Stömmer7, David F Schaeffer2, Matthias Frölich1, Helmut Blum8,9,10, Sebastian Vosberg9,10,11, Philipp A Greif9,10,11, Andreas Jung1,9,10, Thomas Kirchner1,9,10, David Horst1,9,10.   

Abstract

Neuroendocrine carcinomas (NECs) of the colorectum are rare but highly aggressive neoplasms. These tumors show some shared genetic alterations with colorectal adenocarcinomas, and most of them have adjacent glandular adenoma or adenocarcinoma components. However, genetic data on colorectal NECs still are sparse and insufficient for definite conclusions regarding their molecular origin. Based on morphological characterization, panel and whole-exome sequencing, we here present results from an in-depth analysis of a collection of 15 colorectal NECs with glandular components, 10 of which by definition were mixed adenoneuroendocrine carcinomas (MANECs). Among shared genetic alterations of both tumor components, we most frequently found TP53, KRAS and APC mutations that also had highest allele frequencies. Mutations exclusive to glandular or neuroendocrine components outnumbered shared mutations but occurred at lower allele frequencies. Our findings not only provide additional evidence for a common clonal origin of colorectal NECs and adjacent glandular tumor components, but strongly suggest their development through the classical adenoma-carcinoma sequence. Moreover, our data imply early separation of glandular and neuroendocrine components during malignant transformation with subsequent independent mutational evolution.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27586204     DOI: 10.1038/modpathol.2016.150

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  23 in total

1.  Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers.

Authors:  Stefano La Rosa; Alessandro Marando; Daniela Furlan; Nora Sahnane; Carlo Capella
Journal:  Am J Surg Pathol       Date:  2012-04       Impact factor: 6.394

2.  Mixed adenoneuroendocrine carcinomas of the gastrointestinal tract: targeted next-generation sequencing suggests a monoclonal origin of the two components.

Authors:  Maria Scardoni; Emanuele Vittoria; Marco Volante; Borislav Rusev; Samantha Bersani; Andrea Mafficini; Marisa Gottardi; Valeria Giandomenico; Giuseppe Malleo; Giovanni Butturini; Sara Cingarlini; Matteo Fassan; Aldo Scarpa
Journal:  Neuroendocrinology       Date:  2014-10-20       Impact factor: 4.914

3.  Molecular characteristics of colorectal neuroendocrine carcinoma; similarities with adenocarcinoma rather than neuroendocrine tumor.

Authors:  Nobuyoshi Takizawa; Yoshihiro Ohishi; Minako Hirahashi; Shunsuke Takahashi; Kazuhiko Nakamura; Masao Tanaka; Eiji Oki; Ryoichi Takayanagi; Yoshinao Oda
Journal:  Hum Pathol       Date:  2015-08-22       Impact factor: 3.466

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

5.  Genetic evidence for the multi-step progression of mixed glandular-neuroendocrine gastric carcinomas.

Authors:  Kyoung-Mee Kim; Min-Joo Kim; Bo-Kyoung Cho; Sang-Wook Choi; Mun-Gan Rhyu
Journal:  Virchows Arch       Date:  2002-01       Impact factor: 4.064

6.  Microallelotyping defines the monoclonal or the polyclonal origin of mixed and collision endocrine-exocrine tumors of the gut.

Authors:  Daniela Furlan; Roberta Cerutti; Anna Genasetti; Giuseppe Pelosi; Silvia Uccella; Stefano La Rosa; Carlo Capella
Journal:  Lab Invest       Date:  2003-07       Impact factor: 5.662

7.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Authors:  Volker Heinemann; Ludwig Fischer von Weikersthal; Thomas Decker; Alexander Kiani; Ursula Vehling-Kaiser; Salah-Eddin Al-Batran; Tobias Heintges; Christian Lerchenmüller; Christoph Kahl; Gernot Seipelt; Frank Kullmann; Martina Stauch; Werner Scheithauer; Jörg Hielscher; Michael Scholz; Sebastian Müller; Hartmut Link; Norbert Niederle; Andreas Rost; Heinz-Gert Höffkes; Markus Moehler; Reinhard U Lindig; Dominik P Modest; Lisa Rossius; Thomas Kirchner; Andreas Jung; Sebastian Stintzing
Journal:  Lancet Oncol       Date:  2014-07-31       Impact factor: 41.316

8.  Comprehensive molecular characterization of human colon and rectal cancer.

Authors: 
Journal:  Nature       Date:  2012-07-18       Impact factor: 49.962

9.  Mutational spectrum of adult T-ALL.

Authors:  Martin Neumann; Sebastian Vosberg; Cornelia Schlee; Sandra Heesch; Stefan Schwartz; Nicola Gökbuget; Dieter Hoelzer; Alexander Graf; Stefan Krebs; Isabelle Bartram; Helmut Blum; Monika Brüggemann; Jochen Hecht; Stefan K Bohlander; Philipp A Greif; Claudia D Baldus
Journal:  Oncotarget       Date:  2015-02-20

10.  NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.

Authors:  Lydia Meder; Katharina König; Luka Ozretić; Anne M Schultheis; Frank Ueckeroth; Carsten P Ade; Kerstin Albus; Diana Boehm; Ursula Rommerscheidt-Fuss; Alexandra Florin; Theresa Buhl; Wolfgang Hartmann; Jürgen Wolf; Sabine Merkelbach-Bruse; Martin Eilers; Sven Perner; Lukas C Heukamp; Reinhard Buettner
Journal:  Int J Cancer       Date:  2015-09-25       Impact factor: 7.396

View more
  24 in total

Review 1.  Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.

Authors:  Ugo Testa; Elvira Pelosi; Germana Castelli
Journal:  Med Sci (Basel)       Date:  2018-04-13

Review 2.  Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites.

Authors:  Silvia Uccella; Stefano La Rosa; Jasna Metovic; Deborah Marchiori; Jean-Yves Scoazec; Marco Volante; Ozgur Mete; Mauro Papotti
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

3.  Appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-type adenocarcinoma of the appendix.

Authors:  Moritz Jesinghaus; Björn Konukiewitz; Sebastian Foersch; Albrecht Stenzinger; Katja Steiger; Alexander Muckenhuber; Claudia Groß; Martin Mollenhauer; Wilfried Roth; Sönke Detlefsen; Wilko Weichert; Günter Klöppel; Nicole Pfarr; Anna Melissa Schlitter
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

4.  Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas.

Authors:  Moritz Jesinghaus; Björn Konukiewitz; Gisela Keller; Matthias Kloor; Katja Steiger; Magdalena Reiche; Roland Penzel; Volker Endris; Ruza Arsenic; Gratiana Hermann; Albrecht Stenzinger; Wilko Weichert; Nicole Pfarr; Günter Klöppel
Journal:  Mod Pathol       Date:  2017-01-06       Impact factor: 7.842

Review 5.  An Update on the Management of Mixed Neuroendocrine-Non-neuroendocrine Neoplasms (MiNEN).

Authors:  Aasems Jacob; Rishi Raj; Derek B Allison; Heloisa P Soares; Aman Chauhan
Journal:  Curr Treat Options Oncol       Date:  2022-03-26

Review 6.  Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma.

Authors:  Melissa Frizziero; Elaine Kilgour; Kathryn L Simpson; Dominic G Rothwell; David A Moore; Kristopher K Frese; Melanie Galvin; Angela Lamarca; Richard A Hubner; Juan W Valle; Mairéad G McNamara; Caroline Dive
Journal:  Clin Cancer Res       Date:  2022-05-13       Impact factor: 13.801

Review 7.  Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

Review 8.  Challenges in High-grade Neuroendocrine Neoplasms and Mixed Neuroendocrine/Non-neuroendocrine Neoplasms.

Authors:  Stefano La Rosa
Journal:  Endocr Pathol       Date:  2021-03-31       Impact factor: 3.943

Review 9.  An update on the development of concepts, diagnostic criteria, and challenging issues for neuroendocrine neoplasms across different digestive organs.

Authors:  Anne Couvelard; Jérôme Cros
Journal:  Virchows Arch       Date:  2022-03-12       Impact factor: 4.064

10.  The structure-based cancer-related single amino acid variation prediction.

Authors:  Jia-Jun Liu; Chin-Sheng Yu; Hsiao-Wei Wu; Yu-Jen Chang; Chih-Peng Lin; Chih-Hao Lu
Journal:  Sci Rep       Date:  2021-06-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.